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Abstract
Background: Malignant transformation of giant cell tumors of bones, that is, secondary malignant giant cell tumor
of bone, is rare. The most common symptoms are local pain and swelling. There are no prior reports of giant cell
tumor of bone with fever of unknown origin at the onset. Here we present a case of a secondary malignant giant
cell tumor of bone due to malignant transformation 40 years after surgery without radiation therapy, presenting as
fever of unknown origin.
Case presentation: A 75-year-old Asian man presented with a 3-week history of continuous pyrexia and left knee
pain and swelling. He had been diagnosed at age 35 years with a giant cell tumor of bone of his left distal femur
and underwent bone curettage and avascular fibula grafting at that time. Postoperative radiation therapy was not
performed. He remained recurrence-free for 40 years after surgery. At age 75, histopathological findings suggested
a secondary malignant giant cell tumor of bone. The tumor specimen expressed tumor necrosis factor-α. Neoplastic
fever was suspected, and a naproxen test was conducted. His pyrexia showed immediate resolution. Surgery was
performed under a diagnosis of a secondary malignant giant cell tumor of bone with neoplastic fever. His pyrexia
and inflammatory activities diminished postoperatively.
Conclusions: This is the first reported case, to the best of our knowledge, of the detection of a secondary malignant
giant cell tumor of bone based on fever of unknown origin after long-term (40 years) follow-up. After curettage and
bone grafting, giant cell tumor of bone may transform to malignancies within a few years or even decades after surgery.
Therefore, meticulous follow-up is essential. The fever might be attributable to the tumor releasing inflammatory
cytokines. Not only pain and swelling but also continuous pyrexia may suggest the diagnosis of a secondary
malignant giant cell tumor of bone.
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Background
Giant cell tumors of bones (GCTBs) are generally benign,
but there are rare cases showing malignant transformation
during long-term follow-up. Malignant GCTBs are classi-
fied into two types: primary and secondary tumors. Pri-
mary malignant GCTB consists of the benign form with a
malignant component which is simultaneously present
and gradually expands. Secondary malignant GCTBs re-
sult from malignant transformation after various periods
following initial treatment for a benign GCTB, and the re-
ported incidences are very low (0.5 to 5 %) [1, 2]. The
interval until malignant transformation ranges from 10 to
41 years, that is, malignancies can develop even during
very long-term follow-up [3, 4]. The most common symp-
toms of secondary malignant GCTBs are local pain and
swelling [5]. However, to the best of our knowledge, there
are no reports of secondary malignant GCTB presenting
as fever of unknown origin (FUO). Here we describe a
patient with FUO who showed malignant transformation
40 years after surgery for a GCTB. Moreover, continuous
pyrexia excluded infection and allergic reactions from the
possible differential diagnoses and distinguished malignant
GCTB from the benign form of this tumor.
Case presentation
A 75-year-old Asian man presented with a 3-week his-
tory of continuous pyrexia and left knee pain and
swelling. He had been diagnosed with a GCTB of his
left distal femur at age 35 years and was treated with
bone curettage and avascular fibula grafting at that
time. Postoperative radiation therapy was not per-
formed. He remained recurrence-free for 40 years after
surgery. He also had a history of fibrous dysplasia of
the craniofacial bones at 35 years of age. He neither
smoked cigarettes nor drank alcohol. At the initial
consultation for FUO, his temperature was 38.3 °C,
and a slight heat sensation and swelling were noted
around his left knee. The range of motion of his left
knee was restricted to 5 to 70 degrees. A patellar tap
test, for fluid in the knee, was positive. Articular
puncture was performed and the fluid obtained was
cultured; however, no bacteria were identified. His
leukocyte count was 5600/μL (4000 to 8000/μL) and
C-reactive protein (CRP) was 17.8 mg/dL (<0.2 mg/dL),
suggesting increased inflammatory activities. There
were no other abnormalities.
A plain X-ray and computed tomography (CT) showed
bone grafts, including a fibula graft from the femoral
metaphysis to the epiphyseal area that had been per-
formed at the time of the initial surgery 40 years earlier.
Neither bone translucency nor destruction was detected
(Fig. 1). Magnetic resonance imaging (MRI) revealed fluid
retention in his medial femur and intra-articular area. T1-
weighted images of the intra-osseous area showed a low
to isosignal intensity, and T2-weighted images showed an
isosignal to high signal intensity. There were no masses in
the extra-osseous area (Fig. 2). Bone scintigraphy revealed
an abnormal accumulation in his left distal femur (Fig. 3).
Although his bacterial culture revealed no infectious
organisms, based on findings including local symptoms
and the inflammatory activities, surgical debridement in
addition to antibiotic treatment was performed under
clinical suspicion of chronic osteomyelitis of the distal
femur. However, the pyrexia persisted. On histopatho-
logical examination, neither tumor osteoid formation nor
residual areas of GCTB were identified, but dense pro-
liferation of tumor cells with atypia/nuclear division
was indicative of malignant transformation to undifferen-
tiated pleomorphic sarcoma. Thus, rather than chronic
osteomyelitis, a secondary malignant GCTB was diag-
nosed (Fig. 4a). Furthermore, the tumor specimen
expressed tumor necrosis factor-α (TNF-α; Fig. 4b).
Neoplastic fever was suspected, and a naproxen test
was thus conducted. His pyrexia subsided within 24 hours
of administration. There were no metastases except in his
left distal femur. Under a diagnosis of a secondary malig-
nant GCTB with neoplastic fever, his left femur was
Fig. 1 Plain X-ray findings and computed tomography findings.
Plain X-ray (a, b) and computed tomography (c, d) show bone grafts,
including a fibula graft performed at the time of initial surgery involving
transplantation of the femoral metaphysis to the epiphyseal area.
Neither bone translucency nor destruction is apparent on these images
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amputated. Unfortunately, a limb salvage procedure was
not feasible due to widespread dissemination of malignant
cells caused by the previous surgical debridement. There
was no fever postoperatively, and inflammatory activities
diminished markedly. To date, his course has been
favorable.
Discussion
GCTBs are benign bone tumors consisting of two cellular
components: interstitial tumor cells and a large number of
multinuclear giant cells. These tumors most frequently de-
velop in individuals of 20 to 39 years of age. Common
tumor sites are the distal femur and proximal tibia. Local
recurrence rates range from 10 to 25 %. The interval until
local recurrence is reportedly 6 months or less in 25 % of
these patients and 2 years or less in 97 % of these patients
[6]. Therefore, relapse after 5 years or more of follow-up
is extremely rare [1, 2].
Secondary malignant GCTBs, with incidences ranging
from 0.5 to 5 %, represent transformation from the be-
nign to the malignant form of GCTB after surgical treat-
ment [1, 2]. The reported incidences include patients
who underwent surgical treatment both with and with-
out radiation therapy. The development of malignancy a
long time after radiation therapy has been recognized.
Incidences in patients undergoing surgery alone without
radiation therapy are only 0.2 to 2 % [3, 7, 8]. According
to previous reports, transformation to a secondary
malignant GCTB can occur without radiation therapy
10 to 41 years after treatment [3, 4]. GCTBs may also
recur during long-term follow-up. Hence, it is neces-
sary to discriminate between benign and malignant
GCTB in some cases [1, 2]. As previously reported, the
most common primary symptoms of the malignant
form are pain and swelling [5]. However, to the best of
our knowledge, there are no prior reports describing a
patient such as ours with continuous pyrexia as a pri-
mary symptom. The prognosis of patients with second-
ary malignant GCTB is poor [3]. There are no
characteristic symptoms or imaging findings, which
makes early detection difficult [3]. Therefore, continu-
ous pyrexia not due to either infection or an allergic
reaction may facilitate distinguishing malignant GCTB
from the benign form.
Fig. 2 Magnetic resonance imaging. Coronal section: a T1-weighted
image, b T2-weighted image. Transverse section: c T1-weighted image,
d short T1 inversion recovery. Fluid retention can be seen in the medial
femur and intra-articular area. T1-weighted images of the intra-osseous
area show a low to isosignal intensity, and T2-weighted images
showed an isosignal to high signal intensity. There are no masses
in the extra-osseous area
Fig. 3 Bone scintigraphy. There is abnormal accumulation in the left
distal femur. The abnormal accumulation in the craniofacial bones
was attributed to fibrous dysplasia
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Although the mechanism of malignant transformation
remains to be clarified, bone infarction is known to be
involved in the development of sarcomas, such as osteo-
sarcoma, malignant fibrous histiocytoma, and fibrosar-
coma [9, 10]. Furthermore, a previous study documented
malignant transformation at the site of bone grafting [11].
The grafted bone cells may have died, resulting in malig-
nant transformation through repair and growth-related
changes. Our patient had undergone curettage and fibula
grafting, such that malignant cells may have aggregated at
the site of bone grafting. Malignancy may thereby have de-
veloped 40 years after initial treatment.
FUO is defined as “fever persisting for 3 weeks or
more and reaching 38.3°C or higher at least three times,
based on which a definitive diagnosis cannot be made
despite admission/detailed examination for 1 week”. In
60 % of such patients, FUO is related to infection. How-
ever, neoplastic fever accounts for 27 % of those with
non-infectious fever; this percentage is relatively high
[12]. Diagnostic criteria for neoplastic fever are presented
in Table 1. On a naproxen test, naproxen is administered,
and reactions are regarded as positive if pyrexia dimin-
ishes 24 hours after administration. The sensitivity and
specificity of this test are reportedly 92 and 100 %, re-
spectively. The interval from naproxen administration
until antipyretic activity is shorter than that from diclofe-
nac or indomethacin administration [13]. Antipyretic ac-
tivity was reportedly achieved in 50 % of patients treated
with steroids, but 90 % of patients treated with naproxen.
Our patient showed a positive reaction on the naproxen
test, meeting the diagnostic criteria for neoplastic fever.
Although the pathogenesis of neoplastic fever remains to
be clarified, inflammatory cytokines, such as interleukin-1
(IL-1), IL-6, TNF-α, and interferon, are reportedly involved.
Inflammatory cytokines are produced by necrotic tissue or
tumor cells, and these factors act on the hypothalamus
through prostaglandin E2 (PGE2) induction, inducing fever
by raising the set body temperature. Furthermore, TNF-α
acts on the liver, producing CRP and thereby increasing
the CRP level (Fig. 5). The incidence of neoplastic fever in
patients with sarcoma, among malignant neoplasms, is re-
portedly 3.5 % [14]. A prior patient in our care, who had
initially complained of FUO, was found to have a malig-
nant fibrous histiocytoma. Expression of inflammatory
cytokines, such as TNF-α, was detected at the tumor site
[15]. TNF-α was also expressed at the tumor site in the
present case (Fig. 5). After amputation, our patient’s in-
flammatory response diminished. Therefore, the tumor
may have produced inflammatory cytokines.
Conclusions
This is the first report to describe a secondary malig-
nant GCTB detected based on FUO after very long-
term (40 years) follow-up. GCTBs treated by curettage
and bone grafting may become malignant over several
decades following surgery. Therefore, meticulous follow-
up is essential. The origin of the fever might have been the
Fig. 4 Histopathological findings. a Hematoxylin and eosin staining
(×400): neither tumor osteoid formation nor residual areas of giant
cell tumors of bone are present. There is dense proliferation of tumor
cells with atypia/nuclear division. Undifferentiated pleomorphic sarcoma
transformation was diagnosed. b Tumor necrosis factor-α staining (×400):
the tumor specimen expressed tumor necrosis factor-α. HE hematoxylin
and eosin, TNF-α tumor necrosis factor-α.
Table 1 Diagnostic criteria for neoplastic fever
Temperature over 37.8 °C at least once each day
Duration of fever over 2 weeks
Lack of evidence of infection (physical examination, laboratory
examinations, imaging studies)
Absence of allergic mechanisms (drug allergy, transfusion reaction,
and radiation or chemotherapeutic drug reaction)
Lack of response of fever to an empiric, adequate antibiotic therapy
for at least 7 days
Prompt complete lysis of fever by the naproxen test with sustained
normal temperature while receiving naproxen
Takesako et al. Journal of Medical Case Reports  (2016) 10:47 Page 4 of 5
release of inflammatory cytokines from the tumor itself.
Not only pain and swelling but also continuous pyrexia
may facilitate the diagnosis of malignant transformation
of GCTBs.
Consent
Written informed consent was obtained from the patient
for publication of this case report and accompanying im-
ages. A copy of the written consent is available for re-
view by the Editor-in-Chief of this journal.
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Fig. 5 Mechanism of neoplastic fever. Inflammatory cytokines are produced by necrotic tissue or tumor cells, and these factors act on the hypothalamus
through prostaglandin E2 induction, thereby by causing fever by raising the set body temperature. Furthermore, tumor necrosis factor-α acts on the liver,
producing C-reactive protein and thus increasing the serum C-reactive protein level. CRP C-reactive protein, IL-1 interleukin-1, IL-6 interleukin-6,
IL-10 interleukin-10, PGE2 prostaglandin E2, TNF-α tumor necrosis factor-α
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